Cefiderocol is built to tackle the toughest Gram-negative infections. Its unique siderophore “Trojan horse” approach helps the drug slip into Gram-negative bacteria by hijacking iron transport systems, while its stability to many beta-lactamases lets it resist breakdown by enzymes like ESBLs and many carbapenemases. Because of this design, it’s particularly effective against very resistant Gram-negative pathogens such as Pseudomonas, Acinetobacter, and Enterobacterales that produce multiple resistance mechanisms. It does not target Gram-positive bacteria or fungal pathogens, and its strongest justification is for difficult, highly resistant Gram-negative infections rather than moderate ones or non-GN organisms.

MRSA’s resistance to most beta-lactams comes from PBP2a, a penicillin-binding protein with low affinity for beta-lactam antibiotics. Because beta-lactams target PBPs to stop cell wall synthesis, binding to a PBP that beta-lactams don’t effectively engage allows MRSA to continue building its cell wall. Vancomycin works by a different mechanism: it binds directly to the D-Ala-D-Ala terminus of the peptidoglycan precursors, blocking cell wall synthesis regardless of which PBP is present. That’s why vancomycin is commonly effective against MRSA. The other statements don’t fit MRSA’s resistance profile: beta-lactamase-related explanations don’t account for PBP2a-mediated resistance, altering DNA gyrase describes fluoroquinolone resistance, and beta-lactamase inhibitors don’t restore activity against PBP2a-mediated resistance.

Atypical pneumonias are typically caused by organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. These pathogens often lack a typical cell wall or live inside host cells, so antibiotics that target bacterial cell walls or require good oxygen-dependent uptake are less effective. Macrolides work by binding to the 50S ribosomal subunit and inhibiting protein synthesis, which gives them good activity against these atypical organisms. They also penetrate well into lung tissue and intracellularly, making them a reliable choice for treating atypical pneumonia, often as outpatient therapy. In contrast, penicillins and cephalosporins target cell wall synthesis and are less active against atypicals, and SAMPLEaminoglycosides rely on oxygen-dependent uptake and have limited activity and penetration in pneumonia.

Fidaxomicin is used to treat Clostridioides difficile infection, with a key advantage: it lowers the chance of the infection coming back after treatment compared with vancomycin. This drug is a narrow-spectrum macrolide that stays largely in the gut, where C. difficile resides, and it spares much of the normal gut flora. That gut-focused action reduces recurrence, which is a major challenge in CDI management. While vancomycin is effective and commonly used, fidaxomicin’s lower recurrence rate makes it the preferred option in many cases, especially when preventing relapse is a priority. Linezolid isn’t a standard CDI therapy, metronidazole was once used but is now less favored due to inferior outcomes, and vancomycin, though effective, doesn’t typically offer the same reduced recurrence as fidaxomicin.

Metronidazole is the classic nitroimidazole with activity against anaerobic bacteria, Helicobacter pylori (as part of eradication regimens), and protozoa such as Trichomonas vaginalis. It works as a prodrug that, in anaerobic cells, is reduced to reactive species that damage DNA and kill the organism. This mechanism explains its selective effectiveness in anaerobes and protozoa, and why it covers the listed pathogens. Among the options, metronidazole uniquely matches this full spectrum, since the other drugs either lack activity against protozoa or do not reliably target H. pylori in practice.